Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID: NCT00278161
Phase: PHASE2
Status: Completed

Conditions

Eligibility Criteria

Sex: ALL
Age: 18 Years - 70 Years
Healthy Volunteers: Not accepted

Interventions

Pegfilgrastim — BIOLOGICAL
6 mg SQ 24-48 hours after last dose of cyclophosphamide.
Rituximab — BIOLOGICAL
375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
Cyclophosphamide — DRUG
50 mg/kg/day on Days 15, 16, 17, and 18.

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving rituximab and cyclophosphamide together with pegfilgrastim may be effective in treating leukemia or non-Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well giving rituximab and cyclophosphamide together with pegfilgrastim works in treating patients with B-cell leukemia, low-grade non-Hodgkin's lymphoma, or mantle cell lymphoma.